Biofrontera Inc.
BFRI

$7.58 M
Marketcap
$0.98
Share price
Country
$-0.02
Change (1 day)
$3.90
Year High
$0.61
Year Low

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

marketcap

Earnings for Biofrontera Inc. (BFRI)

Earnings in 2023 (TTM): $-20,117,000

According to Biofrontera Inc.'s latest financial reports the company's current earnings (TTM) are $-20,117,000. The earnings displayed on this page is the company's Pretax Income.

Earnings history of Biofrontera Inc.

Annual Earnings

Year Income Before Tax Net Income
2023 $-20,117,000 $-20,131,000
2022 $-608,000 $-640,000
2021 $-37,657,000 $-37,713,000
2020 $-10,923,000 $-10,987,000
2019 $-10,949,000 $-10,982,000